By 2030, VNU-HCM aims to rank among the top 100 universities in Asia, with at least one discipline placed in the world’s top ...
For the first time, VNU-HCM will independently appoint professors and associate professors - part of a state-backed push ...
VnExpress International on MSN
Vietnam National University looks to become leading Asian research university by 2045
Deputy Prime Minister Le Thanh Long has signed a decision approving a program to develop the Vietnam National University, Ho Chi Minh City (VNU-HCM) into one of Asia's leading higher education ...
Detailed price information for Constellation Energy Corp (CEG-Q) from The Globe and Mail including charting and trades.
PM Pham Minh Chinh says building an international financial center is about creating a complete ecosystem of policy, talent, infrastructure, and trust.
Nearly half of Indian organisations continue to depend on manual HR reporting even as investments in HR technology rise, ...
For years, enterprise feedback platforms have dominated the market with bloated implementations and steep pricing. Simplesat is calling them out. Global consumer brands handle thousands of support ...
Many general education schools in the city have integrated AI into teaching and learning, either through dedicated AI lessons or by applying the technology to innovate teaching methods across subjects ...
Infosys (NSE: INFY), (BSE: INFY), (NYSE: INFY), a global leader in next-generation digital services and consulting, delivered $5,099 million in Q3 revenues, year on year growth of 1.7% and sequential ...
For demand deposits, Agribank offers an interest rate of 0.2% per year, higher than the 0.1% per year offered by Vietcombank, ...
Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to become the first rival to Bristol-Myers Squibb's fast-growing Camzyos for ...
Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results